Gauvin David V, Yoder Joshua D, Holdsworth David L, Harter Marci L, May Jonelle R, Cotey Noelle, Dalton Jill A, Baird Theodore J
Department of Neurobehavioral Sciences, MPI Research, 54943 North Main Street, Mattawan, MI 49071, USA.
Department of Neurobehavioral Sciences, MPI Research, 54943 North Main Street, Mattawan, MI 49071, USA.
J Pharmacol Toxicol Methods. 2016 Nov-Dec;82:90-108. doi: 10.1016/j.vascn.2016.08.001. Epub 2016 Aug 14.
The International Conference on Harmonisation's (ICH) Tripartite Guideline on Safety Pharmacology Studies for Human Pharmaceuticals has adopted the requirement that each new test substance must be tested for effects on the central nervous system prior to "first dose in man". This assessment is required to measure, at a minimum, the effects of the substance on general motor activity, behavioral changes, coordination, sensory/motor reflex responses, and body temperatures. To achieve this goal, ICH S7A recommends a neurobehavioral assessment (usually a functional observational battery (FOB) or modified Irwin test), which is generally undertaken in the rat. There seems to be a growing lack of consensus on the value of the FOB to determine CNS safety. This review highlights the importance of the time, effort and cost of training technicians to familiarize with their instrument of measure, so that each observer is better able to identify and document very subtle changes in behavior that will serve to increase the reliability and validity of these assays with respect to CNS safety assessments.
国际协调会议(ICH)关于人用药品安全性药理研究的三方指南要求,每种新的受试物质在“首次人体给药”之前必须进行对中枢神经系统影响的测试。该评估至少需要测量该物质对一般运动活动、行为变化、协调性、感觉/运动反射反应和体温的影响。为实现这一目标,ICH S7A推荐进行神经行为评估(通常是功能性观察组合试验(FOB)或改良的欧文试验),一般在大鼠中进行。对于FOB在确定中枢神经系统安全性方面的价值,似乎越来越缺乏共识。本综述强调了培训技术人员熟悉其测量工具所需的时间、精力和成本的重要性,以便每个观察者能够更好地识别和记录行为中非常细微的变化,这将有助于提高这些试验在中枢神经系统安全性评估方面的可靠性和有效性。